How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Vismodegib Market
- By Indication: Basal Cell Carcinoma, Medulloblastoma, Other Solid Tumors
- By Route of Administration: Oral
- By End User: Hospitals, Specialty Clinics, Oncology Centers
- By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Basal Cell Carcinoma leads By Indication at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 10 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 246 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.154 →
- 11 Company Profiles 10 players: SWOT & benchmarking p.162 →
Full report · locked preview
Everything inside the Vismodegib Market report
A complete, evidence-based study - 11 chapters and 103 sections covering market size, segmentation across 4 axes, regional analysis and 10 company profiles, forecast to 2033.
Segmentation covered
Indication 3
Route of Administration 1
End User 3
Distribution Channel 3
Companies profiled
Genentech (a member of the Roche Group)
Curis Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Mylan N.V. (now part of Viatris)
Apotex Inc.
Sandoz (a Novartis division)
Cipla Limited
Hetero Labs Limited
Lupin Limited
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
10 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Genentech (a member of the Roche Group)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Curis Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Sun Pharmaceutical Industries Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Teva Pharmaceutical Industries Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Mylan N.V. (now part of Viatris)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →Apotex Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Sandoz (a Novartis division)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Cipla Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Hetero Labs Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →Lupin Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$12,179M by 2033 · 10.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Basal Cell Carcinoma65.4
- Medulloblastoma18.4
- Other Solid Tumors16.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,801M → $4,368M · 11.7%
Europe$1,255M → $2,503M · 9.0%
Asia Pacific$1,146M → $2,301M · 9.1%
Latin America$709.3M → $1,706M · 11.6%
Middle East and Africa$545.6M → $1,341M · 11.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.512026
10.532027
10.542028
10.542029
10.552030
10.562031
10.592032
10.602033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Genentech (a member of the Roche Group)18.6
- Curis Inc.19.2
- Sun Pharmaceutical Industries Ltd.10.4
- Teva Pharmaceutical Industries Ltd.10.7
- Mylan N.V. (now part of Viatris)7.2
- Apotex Inc.5.8
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Indication16.1%
Route of Administration30.8%
End User28.4%
Distribution Channel24.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.7
- Europe20.5
- Asia Pacific18.8
- Latin America14.0
- Middle East and Africa11.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Genentech (a member of the Roche Group) | 91 | 99 | 79 | 88 | 84 | 90 | 89 |
| Curis Inc. | 80 | 85 | 92 | 92 | 93 | 84 | 88 |
| Sun Pharmaceutical Industries Ltd. | 63 | 83 | 66 | 66 | 73 | 87 | 73 |
| Teva Pharmaceutical Industries Ltd. | 64 | 57 | 78 | 79 | 63 | 58 | 67 |
| Mylan N.V. (now part of Viatris) | 55 | 56 | 56 | 76 | 52 | 65 | 60 |
| Apotex Inc. | 52 | 61 | 71 | 56 | 46 | 55 | 57 |
| Sandoz (a Novartis division) | 43 | 43 | 43 | 49 | 55 | 53 | 48 |
| Cipla Limited | 51 | 39 | 51 | 35 | 47 | 57 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Genentech (a member of the Roche Group)
- Curis Inc.
- Sun Pharmaceutical Industries Ltd.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Genentech (a member of the Roche Group) | ✓ | ✓ | ✓ | ◐ | ✓ | ✓ |
| Curis Inc. | ✓ | ✓ | ✓ | ◐ | ✓ | ◐ |
| Sun Pharmaceutical Industries Ltd. | ◐ | ◐ | ◐ | ◐ | ✓ | ◐ |
| Teva Pharmaceutical Industries Ltd. | ◐ | ◐ | ◐ | ◐ | − | ◐ |
| Mylan N.V. (now part of Viatris) | ◐ | − | − | ◐ | ◐ | ◐ |
| Apotex Inc. | − | − | ◐ | − | − | − |
| Sandoz (a Novartis division) | − | − | − | − | ◐ | − |
| Cipla Limited | − | − | ◐ | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Genentech (a member of the Roche Group)89
2Curis Inc.88
3Sun Pharmaceutical Industries Ltd.73
4Teva Pharmaceutical Industries Ltd.67
5Mylan N.V. (now part of Viatris)60
6Apotex Inc.57
7Sandoz (a Novartis division)48
8Cipla Limited47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Genentech (a member of the Roche Group)Curis Inc.
Challenger2
Strong scale, closing on the leaders.
Sun Pharmaceutical Industries Ltd.Teva Pharmaceutical Industries Ltd.
Contender2
Focused players with pockets of strength.
Mylan N.V. (now part of Viatris)Apotex Inc.
Niche2
Specialists in a single segment or region.
Sandoz (a Novartis division)Cipla Limited
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Indication in North America, then scale across Vismodegib Market — a $528M beachhead inside a $8.13B market.
Beachhead (SOM)$528Mobtainable near-term
Serviceable (SAM)$3.34Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Basal Cell Carcinoma
Best fit — highest urgency & budget in Indication.
Economic buyer79 fit
Medulloblastoma
Strong fit — clear ROI and a fast path to value.
End user67 fit
Other Solid Tumors
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Indication in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Route of Administration & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel29%
Digital / self-serve19%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Indication leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Vismodegib Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified46%
Sales qualified23%
Evaluation15%
Closed-won7%
$19.4KCAC
$98KLTV
5.1:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Vismodegib Market is a resilient opportunity — $2.16B by 2033, compounding at 5.5%.
TAM · 2025$1.41Btoday
TAM · 2033$2.16Bforecast
CAGR5.5%2027–2033
Cumulative$15.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.16BTotal addressable market
SAM$839MServiceable available market
SOM$168MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.5% CAGR
Demand compounds through 2033, outpacing GDP across Indication.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Indication moving from early to mainstream — durable secular demand.
Consolidation upside
10+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.16BLarge & growingTAM by 2033 at 5.5% CAGR
$839MServiceable nowreachable with today’s model
$168MBeachhead winobtainable near-term share
10+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.69BBear3.6% CAGR
$2.16BBase5.5% CAGR
$2.77BBull7.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Route of Administration optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Vismodegib Market — a $1.74B market by 2033. Plan: grow share from 11.7% to 18.3%.
Market size · 2033$1.74Btotal addressable
Market CAGR5.5%2027–2033
Target share18.3%from 11.7% today
Revenue ambition$319Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 11.7% | 18.3% | At risk |
| Revenue | $194M | $319M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 28.8% | 43.2% | Behind |
| Customer retention | 84.0% | 92.9% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Indication
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Route of Administration capability
A defensible second engine — invest in Route of Administration to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Indication share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Route of Administration
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $48M capacity & capability investment
- Greenlight bolt-on M&A in Route of Administration
- Authorise North America expansion plan
- Fund R&D program for Indication leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Vismodegib Market conversation — a $7.32B market you can size, segment and defend in minutes.
Market size · 2033$7.32Btotal opportunity
Growth7.2%CAGR to 2033
Addressable buyers957+accounts in scope
Typical ROI7.2×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Indication
Goal Grow share in Indication
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.2×return on cost, year one
< 3 mopayback period
$47K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
10+players profiled in this market
Coverage includes
Genentech (a member of the Roche Group)Curis Inc.Sun Pharmaceutical Industries Ltd.Teva Pharmaceutical Industries Ltd.Mylan N.V. (now part of Viatris)Apotex Inc.Sandoz (a Novartis division)Cipla Limited+2 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Vismodegib Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Vismodegib Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Visitor Management System for Hospitals Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportVision Therapy Software Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportVision Testing Equipment Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportVision Test Apparatus Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportVision Screening Machine Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportVision Screening Devices Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportVision Inspection System for Pharmaceutical Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportVision Eye Tracker Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportVision Diagnostic Equipment Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportVision Corrector Market
Market size, share, segmentation and regional forecast.
$923M market · 2025 base year
View reportVisible Scanning Spectrophotometer Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportVisible Light Stick for Anesthesia Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.